Immix Biopharma, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 11400 WEST OLYMPIC BLVD., LOS ANGELES, CA, 90064
Mailing Address 10573 W. PICO BLVD., LOS ANGELES, CA, 90064
Phone (888) 958-1084
Fiscal Year End 1231
EIN 454869378
Financial Overview
FY2024
$22.95M
Total Assets
$9.70M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3 Shelf registration for future offerings | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 10, 2025 | View on SEC |
| 4 Insider stock transaction report | December 10, 2025 | View on SEC |
| 8-K Current report of material events | December 8, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 8, 2025 | View on SEC |
| 8-K Current report of material events | December 8, 2025 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 7, 2025 | View on SEC |
| S-3 Shelf registration for future offerings | October 6, 2025 | View on SEC |
Insider Trading
BUY 2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.